Cargando…
Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies
OBJECTIVE: Many autoantibodies are known to be associated with SLE, although their role in clinical practice is limited because of low sensitivity and weak associations with clinical manifestations. There has been great interest in the discovery of new autoantibodies to use in clinical practice. In...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562534/ https://www.ncbi.nlm.nih.gov/pubmed/34725184 http://dx.doi.org/10.1136/lupus-2021-000531 |
_version_ | 1784593276878192640 |
---|---|
author | Brunekreef, Tammo Limper, Maarten Melchers, Rowena Mathsson-Alm, Linda Dias, Jorge Hoefer, Imo Haitjema, Saskia van Laar, Jacob M Otten, Henny |
author_facet | Brunekreef, Tammo Limper, Maarten Melchers, Rowena Mathsson-Alm, Linda Dias, Jorge Hoefer, Imo Haitjema, Saskia van Laar, Jacob M Otten, Henny |
author_sort | Brunekreef, Tammo |
collection | PubMed |
description | OBJECTIVE: Many autoantibodies are known to be associated with SLE, although their role in clinical practice is limited because of low sensitivity and weak associations with clinical manifestations. There has been great interest in the discovery of new autoantibodies to use in clinical practice. In this study, we investigated 57 new and known antibodies and their potential for diagnostics or risk stratification. METHODS: Between 2014 and 2017, residual sera of all anti-dsDNA tests in the UMC Utrecht were stored in a biobank. This included sera of patients with SLE, patients with a diagnosis of another immune-mediated inflammatory disease (IMID), patients with low (non-IMID) or medium levels of clinical suspicion of SLE but no IMID diagnosis (Rest), and self-reported healthy blood bank donors. Diagnosis and (presence of) symptoms at each blood draw were retrospectively assessed in the patient records with the Utrecht Patient-Oriented Database using a newly developed text mining algorithm. Sera of patients were analysed for the presence of 57 autoantibodies with a custom-made immunofluorescent microarray. Signal intensity cut-offs for all antigens on the microarray were set to the 95th percentile of the non-IMID control group. Differences in prevalence of autoantibodies between patients with SLE and control groups were assessed. RESULTS: Autoantibody profiles of 483 patients with SLE were compared with autoantibody profiles of 1397 patients from 4 different control groups. Anti-dsDNA was the most distinguishing feature between patients with SLE and other patients, followed by antibodies against Cytosine-phosphate-Guanine (anti-CpG) DNA motifs (p<0.0001). Antibodies against CMV (cytomegalovirus) and ASCA (anti-Saccharomyces cerevisiae antibodies) were more prevalent in patients with SLE with (a history of) lupus nephritis than patients with SLE without nephritis. CONCLUSION: Antibodies against CpG DNA motifs are prevalent in patients with SLE. Anti-CMV antibodies are associated with lupus nephritis. |
format | Online Article Text |
id | pubmed-8562534 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-85625342021-11-15 Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies Brunekreef, Tammo Limper, Maarten Melchers, Rowena Mathsson-Alm, Linda Dias, Jorge Hoefer, Imo Haitjema, Saskia van Laar, Jacob M Otten, Henny Lupus Sci Med Biomarker Studies OBJECTIVE: Many autoantibodies are known to be associated with SLE, although their role in clinical practice is limited because of low sensitivity and weak associations with clinical manifestations. There has been great interest in the discovery of new autoantibodies to use in clinical practice. In this study, we investigated 57 new and known antibodies and their potential for diagnostics or risk stratification. METHODS: Between 2014 and 2017, residual sera of all anti-dsDNA tests in the UMC Utrecht were stored in a biobank. This included sera of patients with SLE, patients with a diagnosis of another immune-mediated inflammatory disease (IMID), patients with low (non-IMID) or medium levels of clinical suspicion of SLE but no IMID diagnosis (Rest), and self-reported healthy blood bank donors. Diagnosis and (presence of) symptoms at each blood draw were retrospectively assessed in the patient records with the Utrecht Patient-Oriented Database using a newly developed text mining algorithm. Sera of patients were analysed for the presence of 57 autoantibodies with a custom-made immunofluorescent microarray. Signal intensity cut-offs for all antigens on the microarray were set to the 95th percentile of the non-IMID control group. Differences in prevalence of autoantibodies between patients with SLE and control groups were assessed. RESULTS: Autoantibody profiles of 483 patients with SLE were compared with autoantibody profiles of 1397 patients from 4 different control groups. Anti-dsDNA was the most distinguishing feature between patients with SLE and other patients, followed by antibodies against Cytosine-phosphate-Guanine (anti-CpG) DNA motifs (p<0.0001). Antibodies against CMV (cytomegalovirus) and ASCA (anti-Saccharomyces cerevisiae antibodies) were more prevalent in patients with SLE with (a history of) lupus nephritis than patients with SLE without nephritis. CONCLUSION: Antibodies against CpG DNA motifs are prevalent in patients with SLE. Anti-CMV antibodies are associated with lupus nephritis. BMJ Publishing Group 2021-10-31 /pmc/articles/PMC8562534/ /pubmed/34725184 http://dx.doi.org/10.1136/lupus-2021-000531 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Biomarker Studies Brunekreef, Tammo Limper, Maarten Melchers, Rowena Mathsson-Alm, Linda Dias, Jorge Hoefer, Imo Haitjema, Saskia van Laar, Jacob M Otten, Henny Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies |
title | Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies |
title_full | Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies |
title_fullStr | Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies |
title_full_unstemmed | Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies |
title_short | Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies |
title_sort | microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of cpg dna-binding antibodies |
topic | Biomarker Studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562534/ https://www.ncbi.nlm.nih.gov/pubmed/34725184 http://dx.doi.org/10.1136/lupus-2021-000531 |
work_keys_str_mv | AT brunekreeftammo microarraytestinginpatientswithsystemiclupuserythematosusidentifiesahighprevalenceofcpgdnabindingantibodies AT limpermaarten microarraytestinginpatientswithsystemiclupuserythematosusidentifiesahighprevalenceofcpgdnabindingantibodies AT melchersrowena microarraytestinginpatientswithsystemiclupuserythematosusidentifiesahighprevalenceofcpgdnabindingantibodies AT mathssonalmlinda microarraytestinginpatientswithsystemiclupuserythematosusidentifiesahighprevalenceofcpgdnabindingantibodies AT diasjorge microarraytestinginpatientswithsystemiclupuserythematosusidentifiesahighprevalenceofcpgdnabindingantibodies AT hoeferimo microarraytestinginpatientswithsystemiclupuserythematosusidentifiesahighprevalenceofcpgdnabindingantibodies AT haitjemasaskia microarraytestinginpatientswithsystemiclupuserythematosusidentifiesahighprevalenceofcpgdnabindingantibodies AT vanlaarjacobm microarraytestinginpatientswithsystemiclupuserythematosusidentifiesahighprevalenceofcpgdnabindingantibodies AT ottenhenny microarraytestinginpatientswithsystemiclupuserythematosusidentifiesahighprevalenceofcpgdnabindingantibodies |